SBI Securities’s Kailera Therapeutics KLRA Stock Holding History

SBI Securities’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11	Hold	1	–	–	﹤0.01%	3997
2026 Q2	$22	Buy	+1	New	+$22	﹤0.01%	3833

Other funds holding KLRA

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

SBI Securities's KLRA Position: Q3 2026 in Review

SBI Securities held its Kailera Therapeutics (KLRA) position steady in Q3 2026 at 1 share worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #3997.

SBI Securities first reported a position in KLRA in Q2 2026 and has held it in 2 quarters since. The position peaked at $22 in Q2 2026. 9 funds tracked by Wall St. Rank hold KLRA as of Q3 2026.

SBI Securities held 1 share of Kailera Therapeutics worth $11 as of Q3 2026.
SBI Securities left its Kailera Therapeutics share count unchanged in Q3 2026.
Kailera Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3997 holding.
SBI Securities first reported a position in Kailera Therapeutics in Q2 2026 and has held it in 2 quarters since.
SBI Securities's Kailera Therapeutics position peaked at $22 in Q2 2026.
9 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.